Figure 4.

The frequency of HLA-DR⁺ CD38⁺ Tc17 cells is associated with the CD38 and PD-1 expression, treatment duration and the levels of plasma sCD14 in PLWH. (A) Expression of HLA-DR and CD38 in HLA-DR⁺ CD38⁺ Tc17 cells from healthy individuals and PLWH. In the right panel is shown the summary of the individuals evaluated. (B) Correlation between the frequency of total HLA-DR⁺ CD38⁺ Tc17 cells and the HLA-DR⁺ CD38⁺/HLA-DR⁺ CD38⁻ CD8⁺ T-cells ratio. (C) Frequency of HLA-DR⁺ CD38⁺ Tc17 cells in PLWH with HLA-DR⁺ CD38⁺/HLA-DR⁺ CD38⁻ CD8⁺ T-cells ratio <1.9 or ≥2, as well as healthy individuals. The P-value of the Kruskal-Wallis and Dunn's post-hoc test are shown. (D) Expression of PD-1 in HLA-DR and/or CD38-expressing CD8⁺ T-cells from healthy individuals and PLWH. In the right panel is shown the frequency of PD-1⁺ HLA-DR and/or CD38-expressing CD8⁺ T-cells in healthy individuals and PLWH. (E) Correlation between the frequency of total HLA-DR⁺ CD38⁺ Tc17 cells and the frequency of PD-1⁺ HLA-DR⁺ CD38⁺ CD8⁺ T-cells in healthy individuals and PLWH. (F) Frequency of HLA-DR⁺ CD38⁺ Tc17 cells in PLWH who received HAART for <24 or ≥25 months. (G) Correlation between the frequency of total HLA-DR⁺ CD38⁺ Tc17 cells (red circles), the total HLA-DR⁺ CD38⁺ Tc17/Tc1 cells ratio (black squares) and the levels of plasma sCD14. In (A,D,F) the P-value of the Mann-Whitney test is shown. In (B,E,G) the rho and P-value of the Spearman test are shown. NS, Not statistically significant.